A total of 53 eligible patients will be enrolled on this trial (20 with melanoma and 33 with NSCLC). Individual cohorts of the study can be stopped if insufficient activity is observed in the first stage of that cohort. The study will accrue for approximately 24 months, and will be open for approximately 12 additional months as patients on study are being followed.